In:
International Journal of Cancer, Wiley, Vol. 141, No. 7 ( 2017-10), p. 1469-1477
Abstract:
What's new? Increased expression of vascular endothelial growth factor (VEGF) is associated with a poor prognosis in patients with osteosarcoma. In this study, the authors asked whether the anti‐VEGF drug bevacizumab might enhance standard chemotherapy and improve patient outcomes. Unfortunately, despite promising preclinical studies, the answer was no. The bevacizumab also increased the risk of serious wound‐healing complications. The authors conclude that further evaluation of bevacizumab in osteosarcoma is therefore not warranted. However, the study provides important data regarding the use of antiangiogenic agents when surgical resection of a primary bone tumor is required.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8